Sleeve lobectomy or pneumonectomy: Optimal management strategy using decision analysis techniques

被引:135
作者
Ferguson, MK [1 ]
Lehman, AG [1 ]
机构
[1] Univ Chicago, Dept Surg, Chicago, IL 60637 USA
关键词
D O I
10.1016/S0003-4975(03)01243-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The choice between sleeve lobectomy and pneumonectomy is controversial for patients with early-stage lung cancer and who have acceptable lung function. Methods. We performed a meta-analysis of results of sleeve lobectomy and pneumonectomy published in English from 1990 to 2003. A decision model was developed with 5-year survival, quality-adjusted life years (QALY), and cost effectiveness as the outcomes, and sensitivity analyses were performed. Results. The model favored sleeve lobectomy (3.5 percentage point survival advantage) when the reward was 5-year survival; the results were influenced primarily by the 5-year survival rates for patients who did not develop recurrent cancer. Sleeve lobectomy was strongly favored when the reward was QALY (1.53 QALY advantage). Sleeve lobectomy was more cost effective than pneumonectomy, and had an incremental cost effectiveness ratio of $1,300/QALY. Conclusions. In patients with anatomically appropriate early-stage lung cancer, sleeve lobectomy offers better long-term survival and quality of life than does pneumonectomy and is more cost effective. (Ann Thorac Surg 2003;76:1782-8) (C) 2003 by The Society of Thoracic Surgeons.
引用
收藏
页码:1782 / 1788
页数:7
相关论文
共 46 条
[1]   Disease recurrence after resection for stage I lung cancer [J].
AlKattan, K ;
Sepsas, E ;
Fountain, SW ;
Townsend, ER .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1997, 12 (03) :380-384
[2]  
Allison P.R., 1954, ANN ROY COLL SURG, V25, P20
[3]  
[Anonymous], AJCC CANC STAGING MA
[4]   2ND PRIMARY LUNG-CANCER [J].
ANTAKLI, T ;
SCHAEFER, RF ;
RUTHERFORD, JE ;
READ, RC .
ANNALS OF THORACIC SURGERY, 1995, 59 (04) :863-867
[5]   LOCAL AND/OR DISTANT RECURRENCES IN T1-2/NO-1 NON-SMALL-CELL LUNG-CANCER [J].
CANGEMI, V ;
VOLPINO, P ;
DANDREA, N ;
PUOPOLO, M ;
FABRIZI, S ;
LONARDO, MT ;
PIAT, G .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1995, 9 (09) :473-478
[6]   Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated [J].
Chen, YM ;
Perng, RP ;
Lee, YC ;
Shih, JF ;
Lee, CS ;
Tsai, CM ;
Whang-Peng, J .
ANNALS OF ONCOLOGY, 2002, 13 (01) :108-115
[7]   Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review [J].
Clegg, A ;
Scott, DA ;
Hewitson, P ;
Sidhu, M ;
Waugh, N .
THORAX, 2002, 57 (01) :20-28
[8]   The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer [J].
Coy, P ;
Schaafsma, J ;
Schofield, JA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (04) :1025-1033
[9]   QUALITY-OF-LIFE FOLLOWING THORACOTOMY FOR LUNG-CANCER [J].
DALES, RE ;
BELANGER, R ;
SHAMJI, FM ;
LEECH, J ;
CREPEAU, A ;
SACHS, HJ .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (12) :1443-1449
[10]  
DESLAURIERS J, IN PRESS ANN THORAC